Bruker Corporation Faces Securities Class Action Investigation

Shamis & Gentile P.A., a law firm that advocates for investors who are victims of securities fraud, is investigating potential claims against Bruker Corporation (BRKR).

If you purchased or held Bruker securities and suffered losses, you may be eligible to join this securities investigation and seek compensation.

About Bruker

Bruker is a global provider of scientific instruments and analytical solutions. The company is known for supplying advanced tools and systems that serve researchers in academic, biopharma, and industrial markets.

Headquartered in Billerica, Massachusetts, Bruker has expanded its reach through a series of acquisitions, such as Chemspeed, ELITech, and NanoString.

The Allegations

The investigation centers on whether Bruker may have made misleading statements or omitted material information regarding its financial performance and business outlook during the period from Aug. 6, 2024, through July 20, 2025.

On Aug. 6, 2024, Bruker’s management issued a positive report, describing “well above-market organic growth” and “excellent revenue growth” and raising its full-year 2024 guidance to 14–16% growth (with organic growth of 5–7%). However, the company allegedly omitted any disclosure of an accelerating demand slump in its primary markets, particularly academic research and biopharma. These omissions may have contributed to an inflated stock price, as investors were not made aware of the growing headwinds.

On Feb. 13, 2025, Bruker reported record revenue for Q4 2024 and projected “solid revenue growth… and double-digit EPS growth in 2025”. However, this outlook allegedly omitted the mounting tariff and academic headwinds that management already knew would impact 2025. By May 2025, Bruker slashed its guidance to near-flat growth, revealing that prior statements about a bullish outlook may have been false or misleading.

On May 7, 2025, Bruker’s CEO conceded that academic and tariff impacts would “meaningfully impact” 2025 results, lowering guidance to 0–2% organic growth. Despite this, management claimed Bruker could “mitigate” about half the headwinds, without disclosing that organic Q2 demand was collapsing by 7%. Investors were not told the full extent of the deteriorating conditions.

On July 21, 2025, Bruker announced its Q2 2025 preliminary results, disclosing revenue of approximately $795–798 million (flat year-over-year) with a 7% organic decline and weak bookings due to “soft academic demand” and challenges in U.S. biopharma. This disclosure was far worse than prior guidance and led to a sharp 10% drop in Bruker’s stock price, falling from about $40.56 to $36.82 per share and erasing several hundred million dollars in market value. Notably, this plunge occurred on a day when the S&P 500 and Nasdaq were reaching all-time highs, indicating the drop was specific to Bruker and not driven by broader market trends.

Your Rights and Next Steps

This is an active investigation into whether Bruker and certain executives may have violated federal securities laws by making misleading statements or omitting material facts. Investors who purchased or held Bruker securities and suffered financial losses during the period from Aug. 6, 2024, through July 20, 2025, may have legal rights.

To protect their rights, investors are encouraged to gather documentation of their Bruker purchases and sales, as well as any communications or statements received from the company during the relevant period. Participation in the investigation does not obligate investors to join a lawsuit, but it preserves their ability to seek compensation if a class action is filed.

You May Be Entitled to Compensation

If you purchased or held Bruker securities and suffered losses, you may be eligible to join this securities investigation. Securities investigations move quickly, and there may be deadlines to take action.

To find out if you qualify and to help lawyers assess your potential claim, complete the form below to join the investigation.